La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Hansoh Pharmaceutical Group Croissance future
Future contrôle des critères 2/6
Hansoh Pharmaceutical Group devrait augmenter ses bénéfices et son chiffre d'affaires de 10% et de 9.7% par an respectivement. Le BPA devrait croître de de 9.7% par an. Le rendement des capitaux propres devrait être 12.5% dans 3 ans.
Informations clés
10.0%
Taux de croissance des bénéfices
9.7%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 11.2% |
| Taux de croissance des recettes | 9.7% |
| Rendement futur des capitaux propres | 12.5% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 19 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now
Aug 07
If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity
Jul 16Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt
Jun 24Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year
Jun 06Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
May 23Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
May 01Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?
Mar 28There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump
Mar 04An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued
Feb 16Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Quite Sensibly
Dec 08Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Could Be 25% Below Their Intrinsic Value Estimate
Oct 12Hansoh Pharmaceutical Group's (HKG:3692) Upcoming Dividend Will Be Larger Than Last Year's
Sep 14These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well
Sep 09Calculating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jul 10These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well
Jun 11Calculating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jan 23Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet
Dec 01Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 65% Above Its Share Price
Oct 19Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt
Aug 28An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued
Jun 09Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing
May 19Is Hansoh Pharmaceutical Group (HKG:3692) A Risky Investment?
Apr 22An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 45% Undervalued
Feb 06Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 43% Above Its Share Price
Nov 07Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet
Oct 11A Look At The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Jul 14Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 13,892 | 4,382 | 4,118 | 4,426 | 16 |
| 12/31/2025 | 12,394 | 3,828 | 3,832 | 3,785 | 20 |
| 12/31/2024 | 11,862 | 3,787 | 3,439 | 3,414 | 20 |
| 12/31/2023 | 10,104 | 3,278 | 2,754 | 3,116 | N/A |
| 9/30/2023 | 9,782 | 2,926 | 2,292 | 2,615 | N/A |
| 6/30/2023 | 9,459 | 2,575 | 1,830 | 2,114 | N/A |
| 3/31/2023 | 9,421 | 2,579 | 2,140 | 2,427 | N/A |
| 12/31/2022 | 9,382 | 2,584 | 2,449 | 2,741 | N/A |
| 9/30/2022 | 9,675 | 2,652 | 2,646 | 3,004 | N/A |
| 6/30/2022 | 9,968 | 2,720 | 2,842 | 3,267 | N/A |
| 3/31/2022 | 9,952 | 2,717 | 2,472 | 2,922 | N/A |
| 12/31/2021 | 9,935 | 2,713 | 2,102 | 2,577 | N/A |
| 9/30/2021 | 9,524 | 2,675 | 1,415 | 2,345 | N/A |
| 6/30/2021 | 9,112 | 2,638 | 729 | 2,113 | N/A |
| 3/31/2021 | 8,901 | 2,603 | 840 | 2,252 | N/A |
| 12/31/2020 | 8,690 | 2,569 | 951 | 2,390 | N/A |
| 9/30/2020 | 8,377 | 2,526 | 1,775 | 2,802 | N/A |
| 6/30/2020 | 8,063 | 2,483 | 2,600 | 3,213 | N/A |
| 3/31/2020 | 8,373 | 2,520 | 2,666 | 3,271 | N/A |
| 12/31/2019 | 8,683 | 2,557 | 2,732 | 3,330 | N/A |
| 9/30/2019 | 8,615 | 2,357 | 2,529 | 3,092 | N/A |
| 6/30/2019 | 8,548 | 2,157 | 2,325 | 2,854 | N/A |
| 3/31/2019 | 8,135 | 2,030 | 2,008 | 2,463 | N/A |
| 12/31/2018 | 7,722 | 1,903 | 1,690 | 2,072 | N/A |
| 12/31/2017 | 6,186 | 1,595 | 1,139 | 1,402 | N/A |
| 12/31/2016 | 5,433 | 1,476 | N/A | 1,247 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 3692 ( 10% par an) est supérieure au taux d'épargne ( 2.3% ).
Bénéfices vs marché: Les bénéfices de 3692 ( 10% par an) devraient croître plus lentement que le marché Hong Kong ( 11% par an).
Croissance élevée des bénéfices: Les bénéfices de 3692 devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de 3692 ( 9.7% par an) devrait croître plus rapidement que le marché Hong Kong ( 7.4% par an).
Croissance élevée des revenus: Le chiffre d'affaires de 3692 ( 9.7% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de 3692 devrait être faible dans 3 ans ( 12.5 %).